Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas, Myron S. Czuczman, Christos Emmanouilides, Robin Joyce, Brad L. Pohlman, Nancy L. Bartlett, Gregory A. Wiseman, Norman Padre, Antonio J. Grillo-López, Pratik Multani, Christine A. White

Research output: Contribution to journalArticlepeer-review

1021 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences